Published on 8 Nov 2024 on Benzinga
Baxter International Inc. BAX reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the Wall Street estimate of 78 cents.
This was driven by top-line strength in Medical Products & Therapies and Kidney Care, continued improvements in the integrated supply chain, and disciplined operating expense management.